# Tissue Regenix Group: Profitable and Cash-Generating Growth Strategy 2024

- Link: https://www.directorstalkinterviews.com/tissue-regenix-group-profitable-and-cash-generating-growth-strategy-2024/4121151229
- Published: 2024-04-11T10:27:38+01:00
- Author: Amilia Stone

**Tissue Regenix Group PLC** (LON:TRX) is focused on the development and commercialisation
of two proprietary processing technologies for the repair of soft tissue (dCELL®)
and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics
and dental markets. Investment in tissue processing, manufacturing capacity and 
strong commercial partners, together with its “4S” strategy, has generated six consecutive
reporting periods of strong growth, with the group turning EBITDA-positive in 2023.
New growth in 2024 will deliver a fully profitable, cash-generative, group. The 
cash will be invested to expand capacity even further through Phase 2, starting 
in 2025.

 * **Strategy:** The company is building a global regenerative medicine business
   around its proprietary technology platforms, underpinned by compelling clinical
   outcomes. Phase 1 of its investment programme has grown sales to a point where
   the group is cash-generative, which will be used to expand capacity further with
   Phase 2.
 * **2023 results:** Sales rose 20%, to $29.5m ($24.5m), with BioRinse (+25%) the
   main growth driver, supported by dCELL (+17%). Operating efficiencies and good
   cost control saw TRX become EBITDA-positive in 2023. Gross cash was above forecast
   at $4.65m, with flexibility provided by a $10m revolving debt facility.
 * **Outlook:** Management will continue to build on its successful “4S” strategy
   to drive sales growth and [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news).
   The US remains the main driver, but they are looking to expand its geographical
   reach further in 2024 through commercial distribution agreements, accelerating
   the profitability and cash generation.
 * **Risks:** The long recovery from the pandemic appears to be over. They are carefully
   managing supply chain and its ability to recruit staff has improved; however,
   with limited ability to raise prices, increased supply and labour costs must 
   be offset by greater efficiencies. The company has no need for a capital injection.
 * **Investment summary:** 2023 was a milestone year when Tissue Regenix was fully
   EDITDA-positive and cash-generative in 2H’23. Further anticipated growth in 2024
   will see the group become EBIT-positive and generate additional cash, which will
   be used to expand processing and manufacturing further through Phase 2 of its
   investment programme in 2025. An EV/sales multiple of 4x 2025E sales generates
   a valuation of $158m/£125m.

[240410-Hardman-Tissue-Regenix-TRX-Profitable-and-cash-generative](https://www.directorstalkinterviews.com/wp-content/uploads/2024/04/240410-Hardman-Tissue-Regenix-TRX-Profitable-and-cash-generative.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2024/04/240410-Hardman-Tissue-Regenix-TRX-Profitable-and-cash-generative.pdf)

Share on:
